General MedicationsINTRAMUSCULAR, SUBCUTANEOUSGeneric

EVZIO (AUTOINJECTOR)

NALOXONE HYDROCHLORIDE

Standard Dose

2MG/0.4ML (2MG/0.4ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: Discontinued

Summary

Approval overview EVZIO (AUTOINJECTOR) is listed in Drugs@FDA under application 209862 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 2MG/0.4ML (2MG/0.4ML) Sponsor KALEO INC Submission history Latest submission status date: 2016-10-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview EVZIO (AUTOINJECTOR) is listed in Drugs@FDA under application 209862 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 2MG/0.4ML (2MG/0.4ML) Sponsor KALEO INC Submission history Latest submission status date: 2016-10-19 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Discontinued
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.